Reply

Affiliations

¹ aUniversity of Milano Bicocca, Milano, Italy bHospital Clinic University of Barcelona, Barcelona, Spain cDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy dCenter for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University in Prague, Prague, Czech Republic eDepartment of Cardiology, "Asklepeion" General Hospital, Athens, Greece fINCLIVA Research Institute, University of Valencia and CIBERObn, ISCIII, Madrid, Spain.

Comment

Giuseppe Mancia et al. J Hypertens. 2017 Dec.

. 2017 Dec;35(12):2551-2552.

doi: 10.1097/HJH.0000000000001580.

¹ aUniversity of Milano Bicocca, Milano, Italy bHospital Clinic University of Barcelona, Barcelona, Spain cDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy dCenter for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University in Prague, Prague, Czech Republic eDepartment of Cardiology, "Asklepeion" General Hospital, Athens, Greece fINCLIVA Research Institute, University of Valencia and CIBERObn, ISCIII, Madrid, Spain.

No abstract available

Comment on

The polypill in cardiovascular prevention: evidence, limitations and perspective - position paper of the European Society of Hypertension.
Coca A, Agabiti-Rosei E, Cifkova R, Manolis AJ, Redón J, Mancia G. Coca A, et al. J Hypertens. 2017 Aug;35(8):1546-1553. doi: 10.1097/HJH.0000000000001390. J Hypertens. 2017. PMID: 28448291 Review.
In polypills, as in any recipe, it's ingredients that matter.
Hofstetter L, Rimoldi SF, Messerli FH. Hofstetter L, et al. J Hypertens. 2017 Dec;35(12):2550. doi: 10.1097/HJH.0000000000001581. J Hypertens. 2017. PMID: 29095234 No abstract available.